A cross-sectional study to evaluate the awareness and attitudes of physicians towards reducing the cost of prescription drugs, Mumbai

Applied Health Economics and Health Policy

Volumn 12, Issue 2, 2014, Pages 125-137

  Billa, Gauri ^a   Thakkar, Karan ^b   Jaiswar, Sarita ^b   Dhodi, Dinesh ^b  

^a KEM HOSPITAL   (India)

^b SIR J J GROUP OF HOSPITALS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADULT; ARTICLE; AWARENESS; COST CONTROL; CROSS-SECTIONAL STUDY; DRUG COST; DRUG QUALITY; DRUG SAFETY; FEMALE; GOVERNMENT; HUMAN; HUMAN EXPERIMENT; LIFE; MALE; MIDDLE AGED; NORMAL HUMAN; OBSERVATIONAL STUDY; PATENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUESTIONNAIRE; YOUNG ADULT; ATTITUDE TO HEALTH; ECONOMICS; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; INDIA; PHYSICIAN; STATISTICS AND NUMERICAL DATA;

ADULT; ATTITUDE OF HEALTH PERSONNEL; COST SAVINGS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH EXPENDITURES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INDIA; MALE; MIDDLE AGED; PHYSICIANS; PRESCRIPTION DRUGS; YOUNG ADULT;

EID: 84899075278     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0080-2     Document Type: Article

References (62)

1. National Pharmaceuticals Pricing Policy, 2011 [Internet]. 2011. http://pharmaceuticals.gov.in/mshT2810/FTY2.pdf.
2. Gill J, Taylor D. Health and healthcare in India: national opportunities and global impact [Internet]. 2013. http://www.ucl.ac.uk/pharmacy/documents/ news-docs/healthcareinindiajuly2013.
3. PricewaterhouseCoopers. Healthcare in India: emerging market report 2007 [Internet]. 2007. http://www.pwc.com/en-GX/gx/healthcare/pdf/emerging-market- report-hc-in-india.pdf.
4. National Commission on Macroeconomics and Health Ministry of Health & Family Welfare, Government of India. Report of the National Commission on Macroeconomics and Health [Internet]. New Delhi; 2005. http://www.who.int/ macrohealth/action/Reportof the National Commission.pdf.
5. Eaddy MT, Cook CL, O'Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T [Internet]. 2012 (cited 2013 Oct 15); 37(1):45-55. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3278192&tool=pmcentrez&rendertype=abstract.
6. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. [Internet]. 2005 (cited 2013 Oct 15); 1(3):189-99. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 1661624&tool=pmcentrez&rendertype=abstract.
7. Suggs LS, Raina P, Gafni A, et al. Family physician attitudes about prescribing using a drug formulary. BMC Fam Pract. [Internet]. 2009 (cited 2013 Jul 20); 10:69. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2770461&tool=pmcentrez&rendertype=abstract.
8. Shamima K, Robert S, David S, Bruce P. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern States. JMCP [Internet]. 2008; 14(8):780-9. http://www.amcp.org/data/ jmcp/Oct08-all.pdf.
9. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. Hill S, editor. PLoS Med. [Internet]. Public Library of Science; 2007 (cited 2013 May 31); 4(9):e283. doi:10.1371/journal.pmed.0040283.
10. Von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ [Internet]. 2007;335(7624):806-8. Available from: http://www.emgo.nl/kc/Analysis/statements/observationalstudies-lancet- 2007.pdf.
11. Shrank WH, Young HN, Ettner SL, et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care [Internet]. 2005 (cited 2013 Jul 19); 11(1):16-22. http://www.ncbi.nlm.nih.gov/pubmed/15697096.
12. Banahan BF, Kolassa E. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080-8. (Pubitemid 27431276)
13. Dean A, Sullivan K, Soe M. OpenEpi: open source epidemiologic statistics for public health, version 2.3.1 [Internet]. 2011 (cited 2012 Oct 10). http://www.OpenEpi.com.
14. Urbanski P, Wolf A, Herman WH. Cost-effectiveness issues of diabetes prevention and treatment [Internet]. 2007. https://dpgstorage.s3.amazonaws.com/ dce/resources/cost-effective.pdf.
15. Eaddy MT, Shah M, Lunacsek O, Stanford RH. The burden of illness of hypertension and comorbid diabetes. Curr Med Res Opin [Internet]. 2008 (cited 2013 Jul 20); 24(9):2501-7. http://www.ncbi.nlm.nih.gov/pubmed/18671895.
16. Anand K, Pandav CS, Nath LM. Impact of HIV/AIDS on the national economy of India. Health Policy [Internet]. 1999 (cited 2013 Jul 20);47(3):195-205. http://www.ncbi.nlm.nih.gov/pubmed/10538918.
17. Sharma EK. Killer costs. Bus. Today [Internet]. 2013. http://businesstoday.intoday.in/story/cancer-treatment-cost/1/191785.html.
18. Kannan R. Cancer care can burn a big hole in pocket. The Hindu [Internet]. 2012. http://www.thehindu.com/sci-tech/health/policy-and-issues/ cancer-care-can-burn-a-big-hole-in-pocket/article2866649.ece.
19. Laurance J. The real cancer killer: rip-off prices for drugs set by "profiteering" Big Pharma giants. Indep. [Internet]. 2013. http://www.independent.co.uk/news/uk/home-news/the-real-cancer-killer-ripoff- prices-for-drugs-set-by-profiteering-big-pharma-giants-8591825.html.
20. Srivastava R. National policy for containment of antimicrobial resistance, India. [Internet]. 2011. http://www.ncdc.gov.in/ab-policy.pdf.
21. Marsh Inc. The economic and social impact of emerging infectious disease: mitigation through detection, research, and response [Internet]. 2008. http://www.healthcare.philips.com/main/shared/assets/documents/bioshield/ ecoandsocialimpactofemerginginfectiousdisease-111208.pdf.
22. Jamshed SQ, Hassali MAA, Ibrahim MIM, Babar Z-D. Knowledge attitude and perception of dispensing doctors regarding generic medicines in Karachi, Pakistan: a qualitative study. J Pak Med Assoc [Internet]. 2011 (cited 2013 Jul 20); 61(1):80-3. http://www.ncbi.nlm.nih.gov/pubmed/22368910.
23. Banahan BF. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med [Internet]. American Medical Association; 1997 (cited 2013 Jul 19); 157(18):2080. http://archinte. jamanetwork.com/article.aspx?articleid=623881.
24. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health Pharm [Internet]. 2008; 65:1368-84. http://www.ashp.org/DocLibrary/ BestPractices/MgmtGdlCostManag.aspx.
25. Karki SD, Chandra P, Holden JMC, Shehata H. Impact of team approach on reducing drug costs. Int J Geriatr Psychiatry [Internet]. 1988 (cited 2013 Jul 20); 3(2):89-93. doi:10.1002/gps.930030204.
26. Rawlins MD. Cutting the cost of drug development? Nat Rev Drug Discov [Internet]. 2004;3:360-4. http://archives.who.int/prioritymeds/report/append/ barr-apx4B.pdf. (Pubitemid 38499763)
27. Stafford RS, Radley DC. The potential of pill splitting to achieve cost savings. AJMC [Internet]. 2002; 8(8):706-12. http://www.ajmc.com/publications/ issue/2002/2002-08-vol8-n8/Aug02-152p706-712/.
28. Cross M. Two for the price of one: beauty of pill-splitting catches on [Internet]. Manag Care. 2003. http://www.managedcaremag.com/archives/0302/0302. pillsplitting.html.
29. Meadows M. Saving money on prescription drugs [Internet]. U.S. Food Drug Adm. 2005 (cited 2013 Jan 10). http://www.fda.gov/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/ucm134215.htm.
30. Shrank W, Liberman J, Fischer M, Girdish C, Brennan T, Choudhry N. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45:31-8.
31. Gordon SM. Antibiotic prophylaxis against postoperative wound infections. Cleve Clin J Med [Internet]. 2006 (cited 2013 Jul 20); 73(Suppl-1):S42-45. http://www.ccjm.org/content/73/Suppl-1/S42.abstract.
32. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. Clin Infect Dis [Internet]. 2001 (cited 2013 Jul 20); 33(Supplement-2):S78-83. http://cid.oxfordjournals.org/content/33/Supplement-2/S78.full.
33. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA [Internet]. 2004 (cited 2013 Jul 20); 291(15):1850-6. http://www.ncbi.nlm.nih.gov/pubmed/15100203.
34. Caudill TS, Mitzi SJ, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201-6. (Pubitemid 126445103)
35. Shrank WH, Liberman JN, Fischer MA, et al. Physician perceptions about generic drugs. Ann Pharmacother [Internet]. 2011 (cited 2013 Jun 16); 45(1):31-8. http://www.theannals.com/content/45/1/31.abstract.
36. National Pharmaceutical Pricing Policy [Internet]. Natl. Pharm. Pricing Authority, Gov. India. 2012 (cited 2013 Apr 12). http://www.nppaindia.nic.in/ index1.html.
37. What is Jan Aushadi? [Internet]. Dep. Pharm. Gov. India. http://janaushadhi.gov.in/.
38. Alexander J. Parliamentary panel raps DoP for going slow on Jan Aushadhi Programme [Internet]. PharmaBiz. 2012. http://pharmabiz.com/NewsDetails.aspx? aid=69040&sid=1.
39. Jayaraman K. Troubles beset "Jan Aushadhi" plan to broaden access to generics. Nat Med [Internet]. Nature Publishing Group; 2010 (cited 2013 Jul 20); 16(4):350. doi:10.1038/nm0410-350a.
40. Department of Pharmaceuticals. Drugs Prices Control Order 2013 [Internet]. 2013. http://pharmaceuticals.gov.in/DPCO2013.pdf.
41. Govt. of India. India - Macro-economic Summary: 1999-2000 to 2012-13 (E) [Internet]. Plan. Comm.-Gov. India. 2013. http://planningcommission.gov.in/data/ datatable/2504/databook-1.pdf.
42. Ministry of Labour & Employment. Rashtriya Swasthya Bima Yojana (RSBY)-Highlights [Internet]. Press Inf. Bur. Gov. India. 2013. http://www.pib.nic.in/newsite/erelease.aspx?relid=94269.
43. Dhoot V. Rashtriya Swasthya Bima Yojana: UPA's flagship, opposition's pride. Econ. Times [Internet]. 2011. http://articles.economictimes.indiatimes. com/2011-03-19/news/29146333-1-upa-flagship-poverty-schemes-rsby.
44. Dhoot V. Efficacy of government health cover scheme Rashtriya Swasthya Bima Yojana under scanner. Econ Times [Internet]. 2013. http://articles. economictimes.indiatimes.com/2013-10-08/news/42829102-1-rashtriya-swasthya-bima- yojana-rsby-domesticworkers.
45. Sinha S. Govt-sponsored schemes: Meant for poor, but beyond their reach. Econ Times [Internet]. 2012. http://articles.economictimes.indiatimes.com/2012- 08-29/news/33476145-1-insurance-scheme-rsby-rashtriya-swasthya-bima-yojana.
46. Williams E. Remembering the public's interest in the patent system: a post-grant opposition designed to benefit the public [Internet]. 2006. http://bciptf.org/wp-content/uploads/2011/07/27-EricWilliamsIPTF2006.pdf.
47. Thomas JR. HIV/AIDS drugs, patents and the TRIPS agreement: issues and options [Internet]. Congr Res Serv Libr Congr. 2001. http://www.law.umaryland. edu/marshall/crsreports/crsdocuments/RL31066.pdf.
48. Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. J Pharm Bioallied Sci [Internet]. 2010 (cited 2013 Jul 20); 2(4):290-9. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2996062&tool=pmcentrez&rendertype=abstract.
49. World Trade Organisation. Agreement on trade-related aspects of intellectual property rights [Internet]. 1994. http://www.wto.org/english/res-e/ booksp-e/analytic-index-e/trips-e.htm.
50. Essential Medicines and Health Products Information Portal. Implications of the Doha Declaration on the trips agreement and public health: health economics and drugs series no. 012 [Internet]. World Health Organization; 2002. http://apps.who.int/medicinedocs/en/d/Js2301e/9.html.
51. World Trade Organisation. The separate Doha Declaration explained [Internet]. 2001. http://www.wto.org/english/tratop-e/trips-e/healthdeclexpln-e. htm.
52. Musungu SF, Villanueva S, Blasetti R. Utilizing TRIPS flexibilities for public health protection through south-south regional frameworks [Internet]. Geneva: World Health Organization; 2004. p. 12. http://apps.who.int/ medicinedocs/pdf/s4968e/s4968e.pdf.
53. Haddad WF. Compulsory licensing of life-saving medicines [Internet]. 2013. http://www.equilibri.net/nuovo/es/node/2462.
54. Novartis: India rejects patent plea for cancer drug Glivec [Internet]. BBC News-Bus. 2013 (cited 2013 Dec 1). http://www.bbc.co.uk/news/business- 21991179.
55. LaMattina J. India's solution to costly drugs: ignore patents and control prices: except for home grown drugs [Internet]. Pharma Helathcare-Forbes. 2013 (cited 2013 Dec 1). http://www.forbes.com/sites/johnlamattina/2013/04/08/indias- solution-to-drug-costs-ignore-patents-and-control-prices-except-for-home-grown- drugs/.
56. Maharashtra Food and Drug Administration. Raids conducted by FDA Maharashtra [Internet]. Mumbai; 2008. http://www.fdamah.com/Raid.doc.
57. Sinha K. Maharahstra, TN account for 36% of sub-standard drugs. The Times of India [Internet]. New Delhi; 2012. http://articles.timesofindia.indiatimes. com/2012-08-22/india/33321447-1-spurious-drugs-shortage-of-drug-inspectors- pharmaceutical-tradeinterests.
58. Mahalakshmi B, Raghavan S. Barring the way of fake drugs. Financ Express [Internet]. 2013. http://www.financialexpress.com/news/barring-the-way-of-fake- drugs/1072254/3.
59. Nautiyal S. Maharashtra FDA to implement billing inspections stringently. PharmaBiz [Internet]. Mumbai; 2013. http://www.pharmabiz.com/NewsDetails.aspx? aid=76375&sid=1.
60. Gupta RK, Reddy PS. A calm look on cost analysis of different brands of anti-epileptic drugs. J MGIMS [Internet]. 2011;16(1):64-6. http://medind.nic.in/ jaw/t11/i1/jawt11i1p64.pdf.
61. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy [Internet]. (cited 2013 Jul 20); 15(4):433-40. http://www.ncbi.nlm.nih.gov/pubmed/7479195.
62. Pope N. Generic substitution of narrow therapeutic index drugs. US Pharm [Internet]. 2009;34(6):12-9. http://www.uspharmacist.com/content/s/78/c/13854/.